Can-Fite BioPharma Ltd.
CANF
Rank in Stocks
#31436
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical... Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.
Share Price
$0.82125069
Last synced: 2026-11-11
Market Cap
$3.05M
Change (1 day)
-4.17%
Change (1 year)
-91.18%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Can-Fite BioPharma Ltd. (CANF)
Category
Healthcare
Operating Margin for Can-Fite BioPharma Ltd. (CANF)
Operating Margin as of November 2026 TTM: -2,402.96%
According to Can-Fite BioPharma Ltd.'s latest financial reports, its current operating margin (TTM) is -2,402.96%. At the end of 2025 the company had an operating margin of -2,456.79%.
Operating Margin history for Can-Fite BioPharma Ltd. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -2,402.96% | -2.19% |
| 2025 | -2,456.79% | 103.68% |
| 2024 | -1,206.23% | 9.36% |
| 2023 | -1,102.96% | -11.51% |
| 2022 | -1,246.42% | -17.21% |
| 2021 | -1,505.51% | -18.76% |
| 2020 | -1,853.08% | 213.60% |
| 2019 | -590.90% | 316.92% |
| 2018 | -141.73% | -83.77% |
| 2017 | -873.13% | -82.86% |
| 2016 | -5,093.72% | 30.79% |
| 2015 | -3,894.56% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | -1,018.32% | 101.62% |
| 2010 | -505.07% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.02% |
US
|
|
| -149.01% | -99.94% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Can-Fite BioPharma Ltd.'s operating margin
What is Can-Fite BioPharma Ltd.'s operating margin?
Can-Fite BioPharma Ltd.'s operating margin is -2,402.96%, as of Nov 2026.
What was Can-Fite BioPharma Ltd.'s operating margin in 2025?
In 2025, Can-Fite BioPharma Ltd.'s operating margin was -2,456.79%, compared with -1,206.23% in 2024.
How has Can-Fite BioPharma Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Can-Fite BioPharma Ltd.'s operating margin was highest in 2023 (-1,102.96%) and lowest in 2025 (-2,456.79%).
How does Can-Fite BioPharma Ltd.'s operating margin compare with similar companies?
Can-Fite BioPharma Ltd.'s operating margin (-2,402.96%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.